Contents
Prognostic variables in node-negative and node-positive breast cancer — Introduction.- Routinely available indicators of prognosis in breast cancer.- Prognostic factors for patients with breast cancers 1cm and smaller.- Steroid hormone receptors in breast cancer management.- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.- S-phase fraction and breast cancer — a decade of experience.- Prognostic and predictive value of thymidine labelling index in breast cancer.- Cyclin D1 in breast cancer.- Cyclins and breast cancer.- Prognostic implications of expression of the cell cycle inhibitor p27Kip1.- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.- HER-2/neu as a predictive marker of response to breast cancer therapy.- Prognostic and predictive value of p53 and p21 in breast cancer.- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.- Metalloproteinases and tissue inhibitors of metalloproteinases.- Matrix metalloproteinase inhibitors.- The 67 kDa laminin receptor as a prognostic factor in human cancer.- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis.- Clinical significance of angiogenic factors in breast cancer.- Insulin-like growth factors in human breast cancer.- Molecular prognostic markers in breast cancer.- Prognostic significance of micrometastatic bone marrow involvement.- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis.- Time-dependence of hazard ratios for prognostic factors in primary breast cancer.- Circulatingtumor markers in breast cancer: Accepted utilities and novel prospects.- The relationship between prognostic and predictive factors in the management of breast cancer.- Methodological challenges in the evaluation of prognostic factors in breast cancer.- Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?.- Prognostic variables in node-negative and node-positive breast cancer — editorial.- Author index.
